Ethnic differences in cancer incidence and mortality result from differences in genetic and epidemiologic risk factors. Mutations in BRCA1 and BRCA2 account for a small proportion of all breast cancer cases, but for a much higher proportion of cases with a strong family history of breast or ovarian
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
β Scribed by Michael J. Hall; Julia E. Reid; Lynn A. Burbidge; Dmitry Pruss; Amie M. Deffenbaugh; Cynthia Frye; Richard J. Wenstrup; Brian E. Ward; Thomas A. Scholl; Walter W. Noll
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 208 KB
- Volume
- 115
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Among Asian countries, Pakistan has the highest rates of breast and ovarian cancer. To assess the contribution of the __BRCA1__ and __BRCA2__ germ line mutations to these high rates, we conducted the first study of 176 Pakistani breast and ovarian cancer patients, selected on family his
We report on the screening of the entire BRCA1/BRCA2 coding sequence by SSCP, PTT, and direct sequencing in 68 Italian families with recurrent breast or ovarian cancer. For each investigated proband, the probability of being carrier of a BRCA1/BRCA2 mutation was evaluated using the BRCAPRO software.
## Abstract Index cases from a clinically relevant cohort of 102 Spanish families with at least 3 cases of breast and/or ovarian cancer (at least 1 case diagnosed before age 50) in the same lineage were screened for germline mutations in the entire coding sequence and intron boundaries of the breas
Germline mutations in the BRCA1 and BRCA2 genes are responsible for the predisposition and development of familial breast and/or ovarian cancer. Most mutations of BRCA1 and BRCA2 associated with breast and/or ovarian cancer result in truncated proteins. To investigate the presence of BRCA1 and BRCA2
Sixty high-risk breast and/or ovarian cancer families from North-Eastern Poland were screened for germline mutations in BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185), using a combination of protein truncation test, denaturing high-performance liquid chromatography and direct sequencing. Sixteen (27%)